Survival of children with bone sarcoma in Europe since 1978, European Journal of Cancer, vol.37, issue.6, pp.760-766, 2001. ,
DOI : 10.1016/S0959-8049(01)00004-1
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals Oncol, vol.23, pp.100-109, 2012. ,
Bone cancer : primary bone cancer an bone metastases. 2 nd Edition, 2014. ,
Bone sarcomas: pathogenesis and new therapeutic approaches, IBMS BoneKEy, vol.8, issue.9, pp.402-41410, 1138. ,
DOI : 10.1138/20110531
Mechanisms of bone repair and regeneration, Trends in Molecular Medicine, vol.15, issue.9, pp.417-446, 2009. ,
DOI : 10.1016/j.molmed.2009.07.002
Mesenchymal Progenitors and the Osteoblast Lineage in Bone Marrow Hematopoietic Niches, Current Osteoporosis Reports, vol.117, issue.6, pp.22-32, 2014. ,
DOI : 10.1172/JCI31581
Prospective Review of Mesenchymal Stem Cells Differentiation into Osteoblasts, Orthopaedic Surgery, vol.84, issue.1, pp.13-19, 2017. ,
DOI : 10.2106/00004623-200212000-00001
Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad, STEM CELLS, vol.70, issue.3, pp.397-403, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-1305
URL : http://onlinelibrary.wiley.com/doi/10.1002/stem.596/pdf
Defective Osteogenic Differentiation in the Development of Osteosarcoma, Sarcoma, vol.242, issue.4885, pp.325238-325248, 2011. ,
DOI : 10.1126/science.3201241
Different expression of Sox9 and Runx2 between chondrosarcoma and dedifferentiated chondrosarcoma cell line, European Journal of Cancer Prevention, vol.19, issue.6, pp.466-71, 2010. ,
DOI : 10.1097/CEJ.0b013e32833d942f
Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT, Oncogene, vol.56, issue.9, pp.1095-104, 2012. ,
DOI : 10.1038/onc.2010.135
The Ewing Family of Tumors -- A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts, New England Journal of Medicine, vol.331, issue.5, pp.294-303, 1056. ,
DOI : 10.1056/NEJM199408043310503
Mesenchymal Stem Cell Features of Ewing Tumors, Cancer Cell, vol.11, issue.5, 2007. ,
DOI : 10.1016/j.ccr.2007.02.027
Modeling Initiation of Ewing Sarcoma in Human Neural Crest Cells, PLoS ONE, vol.5, issue.4, 2011. ,
DOI : 10.1371/journal.pone.0019305.s004
Ewing???s sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors, Journal of Clinical Investigation, vol.124, issue.7, 2014. ,
DOI : 10.1172/JCI72399DS1
Development of Ewing's Sarcoma from Primary Bone Marrow???Derived Mesenchymal Progenitor Cells, Cancer Research, vol.65, issue.24, pp.11459-11468, 2005. ,
DOI : 10.1158/0008-5472.CAN-05-1696
Preclinical mouse models of osteosarcoma, BoneKEy Reports, vol.4, 2015. ,
DOI : 10.1038/bonekey.2015.37
Mammalian models of bone sarcomas, Bone Cancer, pp.349-364, 2015. ,
DOI : 10.1016/B978-0-12-416721-6.00030-3
Zebrafish models for studying bone cancers: mutants, transgenic fish and embryos, Bone Cancer, pp.365-370, 2015. ,
DOI : 10.1016/B978-0-12-416721-6.00031-5
Modeling osteosarcoma: in vitro and in vivo approaches, Bone Cancer, pp.195-204, 2015. ,
DOI : 10.1016/B978-0-12-416721-6.00017-0
Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts, Nature Reviews Cancer, vol.111, issue.8, pp.451-452, 2015. ,
DOI : 10.1016/S0092-8674(02)01229-1
Histological heterogeneity of Ewing???s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support, Virchows Archiv, vol.255, issue.5, pp.397-411, 2009. ,
DOI : 10.4161/cc.8.9.8307
Molecular heterogeneity of Ewing sarcoma as detected by ion torrent sequencing. PLoS One, 2016. ,
Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis, PLoS ONE, vol.4, issue.9, 2014. ,
DOI : 10.1371/journal.pone.0107105.s004
DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma, Nature Medicine, vol.9, issue.3, pp.386-395, 2017. ,
DOI : 10.1016/S0893-6080(00)00026-5
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets, Nature Reviews Cancer, vol.9, issue.7, pp.481-489, 1038. ,
DOI : 10.1186/1476-4598-9-17
Who Classification of Tumours of Soft Tissue and Bone. Fourth Edition, IARC Ed, 2013. ,
Molecular oncogenesis of chondrosarcoma, Current Opinion in Oncology, vol.28, issue.4, pp.314-336, 2016. ,
DOI : 10.1097/CCO.0000000000000300
Chondrosarcoma of bone, 3<551::AID-CNCR2820050317>3.0.CO, pp.551-77, 1952. ,
Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma, Genes, Chromosomes and Cancer, vol.51, issue.10, pp.899-909, 2012. ,
DOI : 10.1002/gcc.20937
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours, The Journal of Pathology, vol.6, issue.3, pp.334-377, 2011. ,
DOI : 10.1371/journal.pgen.1000991
Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma, Nature Genetics, vol.26, issue.8, pp.923-929, 2013. ,
DOI : 10.1093/bioinformatics/btq330
The Etiology of Osteosarcoma, Cancer Treat Res, vol.152, pp.15-32, 2009. ,
DOI : 10.1007/978-1-4419-0284-9_2
Risk factors for survival and local control in chondrosarcoma of bone, The Journal of Bone and Joint Surgery, vol.84, issue.1, pp.93-102, 2002. ,
DOI : 10.1302/0301-620X.84B1.11942
Bone and haematopoietic defects in mice lacking c-fos, Nature, vol.360, issue.6406, pp.741-745, 1038. ,
DOI : 10.1038/360741a0
c-fosinduced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos, Cancer Res, vol.55, pp.6244-62451, 1995. ,
Li???Fraumeni Syndrome, Journal of Pediatric Genetics, vol.05, issue.02, pp.84-92, 2016. ,
DOI : 10.1055/s-0036-1579759
Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma, Neoplasia, vol.18, issue.8, 2016. ,
DOI : 10.1016/j.neo.2016.06.008
IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells, BMC Cancer, vol.86, issue.1, pp.552-562, 2015. ,
DOI : 10.1002/path.4256
THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST., The Lancet, vol.133, issue.3421, pp.571-574 ,
DOI : 10.1016/S0140-6736(00)49915-0
OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochim Biophys Acta, vol.1704, 2004. ,
URL : https://hal.archives-ouvertes.fr/inserm-00669006
Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients, Cancer Research, vol.70, issue.19, pp.7610-7619, 1158. ,
DOI : 10.1158/0008-5472.CAN-09-4272
URL : http://cancerres.aacrjournals.org/content/canres/70/19/7610.full.pdf
Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process, Cancer Research, vol.70, issue.24, pp.10329-10368, 1158. ,
DOI : 10.1158/0008-5472.CAN-10-0578
URL : https://hal.archives-ouvertes.fr/inserm-00667504
Therapeutic Approach of Primary Bone Tumours by Bisphosphonates, Current Pharmaceutical Design, vol.16, issue.27, pp.2981-2988, 2010. ,
DOI : 10.2174/138161210793563554
URL : https://hal.archives-ouvertes.fr/inserm-00511241
Bisphosphonates Inhibit Osteosarcoma-Mediated Osteolysis Via Attenuation of Tumor Expression of MCP-1 and RANKL, Journal of Bone and Mineral Research, vol.80, issue.7, pp.1431-1476, 2014. ,
DOI : 10.1038/labinvest.3780115
Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption, Cancer Research, vol.67, issue.15, pp.7308-7326, 1158. ,
DOI : 10.1158/0008-5472.CAN-06-4130
Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases, Cancer Res, vol.70, pp.7063-72, 2010. ,
Osteoclasts are important for bone angiogenesis, Blood, vol.115, issue.1, pp.140-149, 2010. ,
DOI : 10.1182/blood-2009-08-237628
The role of osteoclasts and tumourassociated macrophages in osteosarcoma metastasis, Biochim Biophys Acta, vol.1826, pp.434-476, 2012. ,
Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence, PLoS ONE, vol.17, issue.6, 2010. ,
DOI : 10.1371/journal.pone.0010999.s001
URL : https://hal.archives-ouvertes.fr/inserm-00667931
Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion, PLOS ONE, vol.12, issue.4, 2016. ,
DOI : 10.1371/journal.pone.0166500.t001
URL : https://doi.org/10.1371/journal.pone.0166500
The effect of extracellular acidosis on the behaviour of mesenchymal stem cells in vitro, European Cells and Materials, vol.33, pp.252-267, 2017. ,
DOI : 10.22203/eCM.v033a19
Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-??B activation, International Journal of Cancer, vol.17, issue.Suppl 5, pp.1331-1345, 2017. ,
DOI : 10.2174/1389450117666160307143226
Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip, European Journal of Cell Biology, vol.96, issue.2, pp.110-118, 2017. ,
DOI : 10.1016/j.ejcb.2017.01.003
URL : https://hal.archives-ouvertes.fr/inserm-01466071
Connexin 43 Channels Are Essential for Normal Bone Structure and Osteocyte Viability, Journal of Bone and Mineral Research, vol.292, issue.2, pp.436-484, 2015. ,
DOI : 10.1152/ajpcell.00611.2005
URL : http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2374/pdf
Communication intercellulaire et remodelage osseux, Biologie Aujourd'hui, vol.25, issue.2, pp.125-159, 2012. ,
DOI : 10.1016/S8756-3282(99)00227-6
Connexins and Pannexins in Bone and Skeletal Muscle, Current Osteoporosis Reports, vol.8, issue.Pt 1, pp.326-334, 2017. ,
DOI : 10.3389/fncel.2014.00405
Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1832, issue.4, pp.553-64, 2013. ,
DOI : 10.1016/j.bbadis.2013.01.001
Multimodal transfer of MDR by exosomes in human osteosarcoma, International Journal of Oncology, vol.49, issue.1, 2016. ,
DOI : 10.3892/ijo.2016.3509
Blocking tumoreducated MSC paracrine activity halts osteosarcoma progression, Clin Cancer Res, 2017. ,
DOI : 10.1158/1078-0432.ccr-16-2726
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005. ,
DOI : 10.1016/j.bone.2005.02.020
The Central Regulation of Bone Mass, The First Link between Bone Remodeling and Energy Metabolism, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.11, pp.4795-801, 2010. ,
DOI : 10.1210/jc.2010-1030
Neuronal Control of Bone Remodeling, Toxicologic Pathology, vol.19, issue.7, 2017. ,
DOI : 10.1016/j.cell.2007.05.038
The Central Nervous System and Bone Metabolism: An Evolving Story, Calcified Tissue International, vol.17, issue.6, pp.476-485, 2017. ,
DOI : 10.1152/ajpendo.00048.2014
Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells, Biochemical Pharmacology, vol.61, issue.3, pp.6-295200544, 2001. ,
DOI : 10.1016/S0006-2952(00)00544-X
Efficacy of Continuously Administered PEDF-Derived Synthetic Peptides against Osteosarcoma Growth and Metastasis, Journal of Biomedicine and Biotechnology, vol.51, issue.3, pp.230298-230308, 2012. ,
DOI : 10.1167/iovs.09-4455
Antiproliferative , pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma, Oncotarget, vol.8, pp.54459-54471, 2017. ,
Osteoclast inhibition impairs chondrosarcoma growth and bone destruction, Journal of Orthopaedic Research, vol.3, issue.12, pp.1562-71, 2014. ,
DOI : 10.1186/2191-219X-3-40
URL : http://onlinelibrary.wiley.com/doi/10.1002/jor.22714/pdf
Macrophage infiltration predicts a poor prognosis for human ewing sarcoma, French Sarcoma Group (GSF-GETO) (2016) Zoledronate in, pp.1157-70, 2011. ,
Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours, Clinical Sarcoma Research, vol.157, issue.1, pp.13-23, 2016. ,
DOI : 10.1016/S0002-9440(10)64850-X
The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cellular Immunol, in press ,
URL : https://hal.archives-ouvertes.fr/inserm-01644725
Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma, BMC Cancer, vol.17, issue.1, pp.123-133, 2005. ,
DOI : 10.1080/08880010050034283
Long-Term Results of Intralesional Curettage and Cryosurgery for Treatment of Low-Grade Chondrosarcoma, The Journal of Bone and Joint Surgery-American Volume, vol.95, issue.15, pp.1358-1364, 2013. ,
DOI : 10.2106/JBJS.L.00442
The Clinical Management of Chondrosarcoma, Current Treatment Options in Oncology, vol.93, issue.5, pp.94-106, 2009. ,
DOI : 10.1016/j.ijrobp.2006.08.027
Drugs in early clinical development for the treatment of osteosarcoma, Expert Opinion on Investigational Drugs, vol.50, issue.6, 2016. ,
DOI : 10.1038/srep20944
URL : https://hal.archives-ouvertes.fr/inserm-01466096
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival???A Report From the Children's Oncology Group, Journal of Clinical Oncology, vol.26, issue.4, pp.633-641, 1200. ,
DOI : 10.1200/JCO.2008.14.0095
Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?, Expert Opinion on Emerging Drugs, vol.126, issue.15, pp.339-52, 2013. ,
DOI : 10.1097/JTO.0b013e31826aec2b
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration, Journal of Clinical Oncology, vol.33, issue.27, pp.3036-3082, 2015. ,
DOI : 10.1200/JCO.2014.59.5256
Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials, PLOS ONE, vol.34, issue.7, 2015. ,
DOI : 10.1371/journal.pone.0133569.s003
Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression, Clinical Cancer Research, vol.21, issue.5, pp.1139-50, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-1882
The proliferation rate paradox in antimitotic chemotherapy, Molecular Biology of the Cell, vol.23, issue.1, pp.10-14, 2012. ,
DOI : 10.1091/mbc.E10-04-0335
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers, Journal of Bone Oncology, vol.4, issue.1, 2015. ,
DOI : 10.1016/j.jbo.2015.01.001
Targeted therapies for bone sarcomas, BoneKEy Reports, vol.2, 2013. ,
DOI : 10.1038/bonekey.2013.112
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817966/pdf
Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients, Acta Oncologica, vol.2, issue.10, 2014. ,
DOI : 10.1200/JCO.2006.07.3049
Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma, Rare Tumors, vol.7, issue.2, 2015. ,
DOI : 10.4081/rt.2015.5992
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.18, issue.9, pp.2658-67, 1158. ,
DOI : 10.1158/1078-0432.CCR-11-1900
Alpha Emitter Radium 223 in High-Risk Osteosarcoma, JAMA Oncology, vol.1, issue.2, pp.253-255, 2015. ,
DOI : 10.1001/jamaoncol.2014.289
Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, vol.58, issue.7391, pp.570-575, 1038. ,
DOI : 10.1101/gr.1239303
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy, BMC Cancer, vol.10, issue.1, pp.813-823, 2014. ,
DOI : 10.1016/0197-2456(89)90015-9
Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway, European Journal of Cancer, vol.53, 2016. ,
DOI : 10.1016/j.ejca.2015.09.009
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome, Frontiers in Pharmacology, vol.8, 2017. ,
DOI : 10.1038/nri2326
Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors, Pediatric Blood & Cancer, vol.11, issue.5, 2017. ,
DOI : 10.1016/j.ccr.2007.02.027
Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas, Medical Oncology, vol.8, issue.12, pp.93-103, 2016. ,
DOI : 10.1097/JTO.0b013e318292be18
Programmed Cell Death Ligand 1 Expression in Osteosarcoma, Cancer Immunology Research, vol.2, issue.7, pp.690-698, 2014. ,
DOI : 10.1158/2326-6066.CIR-13-0224
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy, Cancer Immunology, Immunotherapy, vol.3, issue.Suppl 3, pp.119-128, 2017. ,
DOI : 10.1186/s40425-015-0067-z
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas, Clinical Sarcoma Research, vol.29, issue.6, 2016. ,
DOI : 10.1038/onc.2009.381
Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults, Pediatric Blood & Cancer, vol.18, issue.4, pp.1780-1785, 2016. ,
DOI : 10.1038/mt.2010.24
Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas, Cancer Chemotherapy and Pharmacology, vol.24, issue.3, pp.855-860, 2012. ,
DOI : 10.1097/CCO.0b013e3283528b73
Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model, PLoS ONE, vol.8, issue.6, 2012. ,
DOI : 10.1371/journal.pone.0032458.s002
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype, Modern Pathology, vol.29, issue.9, pp.1028-1065, 2016. ,
DOI : 10.1097/CJI.0000000000000065
Population-based study of giant cell tumor of bone in Sweden (1983???2011), Cancer Epidemiology, vol.42, pp.82-89, 1983. ,
DOI : 10.1016/j.canep.2016.03.014
Giant-cell tumor: A study of 195 cases, 5<1061::AID- CNCR2820250509>3.0.CO, pp.1061-107010, 1970. ,
DOI : 10.1002/1097-0142(197005)25:5<1061::AID-CNCR2820250509>3.0.CO;2-E
Surveillance for lung metastasis from giant cell tumor of bone, Journal of Surgical Oncology, vol.37, issue.7, 2017. ,
DOI : 10.21873/anticanres.11373
RANK-RANKL signalling in cancer, Bioscience Reports, vol.36, issue.4, pp.366-376, 2016. ,
DOI : 10.1042/BSR20160150
URL : https://hal.archives-ouvertes.fr/inserm-01644732
Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone, European Journal of Cancer, vol.50, issue.14, 2014. ,
DOI : 10.1016/j.ejca.2014.06.003
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study, The Lancet Oncology, vol.14, issue.9, pp.901-909, 2013. ,
DOI : 10.1016/S1470-2045(13)70277-8